Novo Nordisk: acquisition of Catalent approved
(CercleFinance.com) - All regulatory closing conditions relating to the review of Novo Holdings' pending acquisition of Catalent have been met.
The parties are now free to close the transaction, as well as Novo Nordisk's subsequent acquisition of three Catalent manufacturing sites from Novo Holdings A/S.
The agreement to acquire the three manufacturing sites was announced on 5 February, 2024.
Novo Nordisk now expects the acquisition to close in the next few days.
Once completed, the acquisition is expected to impact the financial outlook published on 6 November 2024, with a single-digit negative impact on operating income growth and a negative impact on free cash flow, with an acquisition price of $11.7bn.
In 2025, the acquisition is expected to have a single-digit negative impact on operating income growth.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
The parties are now free to close the transaction, as well as Novo Nordisk's subsequent acquisition of three Catalent manufacturing sites from Novo Holdings A/S.
The agreement to acquire the three manufacturing sites was announced on 5 February, 2024.
Novo Nordisk now expects the acquisition to close in the next few days.
Once completed, the acquisition is expected to impact the financial outlook published on 6 November 2024, with a single-digit negative impact on operating income growth and a negative impact on free cash flow, with an acquisition price of $11.7bn.
In 2025, the acquisition is expected to have a single-digit negative impact on operating income growth.
Copyright (c) 2024 CercleFinance.com. All rights reserved.